Study of Novel Treatment Combinations in Patients With Lung Cancer

Prior treatment

• Active serious infection within 4 weeks prior to study treatment.
  • Substudy 01 and 02
• Received previous anticancer therapy within 4 weeks prior to enrollment.
  • Substudy 03: All Experimental arms
• NSCLC previously treated with systemic therapy or radiotherapy.
• Received prior treatment with any anti-PD-(L)-1 or other immune checkpoint inhibitors (CPIs).
  • Note: Other protocol defined inclusion/exclusion criteria may apply

Other illness

• Mixed small-cell lung cancer and NSCLC histology.
• Active second malignancy.
• Active autoimmune disease.
• History of or current non-infectious pneumonitis/interstitial lung disease.

Other

• All Substudies:
• Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

• All Substudies:
• Histologically or cytologically documented non-small-cell lung cancer (NSCLC).
• No known actionable genomic alterations for which targeted therapies are available.
• Eastern cooperative oncology group (ECOG) performance status score of 0 or 1.
• Measurable disease per response evaluation criteria in solid tumors.
• Adequate hematologic and end-organ function.
• Individuals of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception.
  • Substudy 01: All Experimental arms
• Stage IV NSCLC.
• For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative.
• PD-L1 status by central confirmation.
• No prior systemic treatment for metastatic NSCLC.
  • Substudy 02: All Experimental arms
• Stage IV NSCLC.
• In individuals with nonsquamous histology and actionable EGFR, ALK, or other known genomic alterations must have received treatment with at least 1 targeted therapy to the appropriate genomic alteration.
  • Substudy 03: All Experimental arms
• Previously untreated individuals with resectable (Stage II, IIIA, IIIB (T\[3-4\]N2) NSCLC (per American Joint Committee on Cancer (AJCC) Edition 8).
• Planned surgery must comprise of lobectomy, sleeve lobectomy, or bi-lobectomy.
• PD-L1 status by central confirmation.
• For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative.